Fulvestrant+Abemaciclib With or Without Run-In of Fulvestrant in Er-Positive, Her2-Negative Metastatic Breast Cancer
Condition(s):ER-Positive Breast Cancer; HER2-negative Breast CancerLast Updated:January 18, 2023Recruiting
Hide Studies Not Open or Pending
Condition(s):ER-Positive Breast Cancer; HER2-negative Breast CancerLast Updated:January 18, 2023Recruiting
Condition(s):Breast CancerLast Updated:May 14, 2021Completed
Condition(s):PIK3CA Mutation; Solid Tumor, Adult; HER2-negative Breast Cancer; Breast Cancer; Metastatic Breast Cancer; Advanced Breast Cancer; Unresectable Solid TumorLast Updated:November 21, 2022Recruiting
Condition(s):Breast CancerLast Updated:January 6, 2022Not yet recruiting
Condition(s):Advanced Breast Cancer; Metastatic Breast Cancer; Breast Cancer; Breast Carcinoma; Cancer of the Breast; Cancer of Breast; Malignant Tumor of Breast; Breast TumorLast Updated:August 5, 2022Withdrawn
Condition(s):Locally Advanced or Metastatic Breast CancerLast Updated:June 13, 2022Recruiting
Condition(s):Advanced Breast CancerLast Updated:November 28, 2022Recruiting
Condition(s):Postmenopausal Women With ER+ HER2- Primary Breast CancerLast Updated:February 6, 2020Completed
Condition(s):Breast CancerLast Updated:November 30, 2020Recruiting
Condition(s):ER-positive Breast Cancer; HER2-negative Breast Cancer; Metastatic CancerLast Updated:January 26, 2023Recruiting
At TrialBulletin.com, we keep tabs on over 200,000 clinical trials in the US and abroad, using medical data supplied directly by the US National Institutes of Health. Please see the About and Contact page for details.